Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Nikkei erases early gains as profit-taking offsets upbeat earnings

Published 29/01/2021, 04:12
© Reuters.

TOKYO, Jan 29 (Reuters) - Japanese shares slipped on Friday,
giving up early gains, as a boost from technology companies
reporting upbeat earnings was overshadowed by investors'
profit-taking and rebalancing at the end of month.
Still, the market is on course to post its third straight
month of gains, with the Nikkei still hovering below a 30-year
high touched earlier in the month.
Japan's Nikkei share average .N225 slipped 0.18% to
28,145.63 by midday, after gaining 0.44% earlier in the session.
The broader Topix .TOPX was down 0.07% at 1,837.60.
"It appears pension funds are reducing their positions as
they change their allocation at the end of month," said a trader
at a Japanese brokerage.
That also hit some chip-related shares which had benefited
from strong earnings reports.
Advantest 6857.T eased 0.4%, erasing earlier gains of 5.1%
after the company raised its profit forecast for the year ending
in March, citing strong demand for its chip-testing machines.
Tokyo Electron 8035.T slipped 2.7%, reversing gains of
2.4% after the chip manufacturing machine maker hiked its annual
guidance for a second time in the current financial year.
Canon 7751.T fell 5.4%, after gaining about 50% this month
as the maker of camera and printer announced a solid earnings
growth in the last quarter as expected. However, some other companies managed to maintain their
share gains after reporting strong results. Among tech stocks,
Fujitsu 6702.T gained 3.8% and Shinko Electric 6967.T rose
8.9%. Nomura Real Estate 3231.T rose 5.7% and Oriental Land
4661.T gained 2.4% following quarterly results which showed a
stronger-than-expected recovery of the Tokyo Disney Resort.
JCR Pharma extended its gains to its third day, rising
20.4%, as its upbeat earnings announced on Thursday added to the
bullish mood spurred by the news that AstraZeneca AZN.L will
license the firm to produce some 90 million doses of its
COVID-19 vaccine

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.